Consolidated Statement of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net loss	$ (28,978,763)	$ (22,000,556)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	5,181	5,182
Amortization of employees, directors and consultants stock options	3,456,895	6,085,673
Change in fair value of warrant liability	3,915,393	(3,644,601)
Gain on warrant exchange	(2,228,697)
Change in operating assets and liabilities:
Prepaid clinical costs	144,528	195,172
Prepaid expenses and other assets	(171,021)	538,073
Operating lease right-of-use asset	150,269	297,596
Accounts payable and other current liabilities	1,015,088	(865,006)
Severance payable	(58,896)	(428,242)
Accrued bonuses	(760,269)	305,731
Operating lease liability	(54,186)	(49,333)
Net cash used in operating activities	(23,564,478)	(19,560,311)
Cash flows from financing activities:
Insurance note payments	(518,124)	(597,339)
Proceeds from registered offerings, net of issuance costs	99,547,283	32,555,738
Proceeds from exercise of stock options	5,351,323
Net cash provided by financing activities	104,380,482	31,958,399
Net increase in cash	80,816,004	12,398,088
Cash and cash equivalents — beginning of year	26,700,416	14,302,328
Cash and cash equivalents — end of year	107,516,420	26,700,416
Cash paid for interest and income taxes are as follows:
Interest	97,133	114,243
Noncash investing and financing activities:
Financing of insurance premiums		$ 518,124
Operating lease right-of-use asset obtained in exchange for lease liabilities	75,439
Share Exchange Agreements [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on warrant exchange	$ (1,900,000)